What's New in Hyponatremia? Parts One and Two of a Journal Club Discussion of the Latest Evidence-Based Literature

Presented by the University of Virginia School of Medicine.

Supported by an educational grant from Otsuka America Pharmaceutical, Inc.

Scroll to the Bottom of this Information to Begin this Course

Release date: September 30, 2014

Valid through: September 30, 2015

Specialty: Hospitalists

Topic: Hyponatremia

Media: Internet

Estimated Time to Complete Activity: 30 minutes per Journal Club

Target Audience

These activities have been designed to meet the educational needs of hospitalists and other general internal medicine providers at hospitals who are involved in the perioperative care of patients with hyponatremia. No prerequisites required.

Program Overview

Hyponatremia is the most common electrolyte abnormality seen in hospitalized patients, and even in its mildest form, it is associated with increased morbidity and mortality. The burden of hyponatremia in the hospital setting is substantial and is expected to increase as the population ages. Being able to adequately treat patients requires hospitalists to clearly diagnose hyponatremia and its underlying etiology. Unfortunately, optimal treatment strategies are not well defined due to the marked differences in symptoms and clinical outcomes based on the chronicity and severity of hyponatremia. These archived web-based journal clubs address the latest published literature on diagnosing and managing patients with hyponatremia, including clinical studies on current and emerging therapies and published patient cases.

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • ANALYZE the most current evidence-based literature regarding the diagnosis and management of hyponatremia.

Credit Available

  • Physicians — 0.5 credits per journal club

All other healthcare professionals completing this course will be issued a statement of participation.

Participating Faculty

Mitchell H. Rosner, MD, FACP (Course Director)
Henry B. Mulholland Professor of Medicine
Chairman, Department of Medicine
University of Virginia Health System
Charlottesville, Virginia

Joseph Verbalis, MD
Professor of Medicine and Physiology
Chief of the Division of Endocrinology and Metabolism
Georgetown University
Washington, DC

Accreditation Statement

The University of Virginia School of Medicine awards hours of participation (equivalent to AMA PRA Category 1 Credit(s)™) to each nonphysician participant who successfully completes this educational activity. The University of Virginia School of Medicine maintains a permanent record of participation for six (6) years.

Credit Designation

The University of Virginia School of Medicine designates this enduring materials for a maximum of 0.5 AMA PRA Category 1 Credits™ per Journal Club. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Mitchell H. Rosner, MD, FACP, reports serving as a consultant for Johnson & Johnson, Novartis, and Otsuka America Pharmaceutical, Inc.

Joseph Verbalis, MD, reports serving as a consultant for Cornerstone Therapeutics Inc; serving as a consultant and on the advisory committee/board for Ferring Pharmaceuticals; and performing industry funded research/serving as an investigator, serving as a consultant, and serving on the speakers' bureau/as a faculty member/peer reviewer, and serving on the advisory committee/board for Otsuka America Pharmaceutical, Inc.

The faculty and staff of the University of Virginia Office of Continuing Medical Education have no financial affiliations to disclose.

Instructions for Participation and Credit

Please complete the pre-test, listen to and view the selected activity, and complete the post-test and evaluation to receive CME credit for this activity. A certificate of participation will be available online immediately following successful completion of the activity.

Hardware and Software Requirements

Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.

Disclosure of Unlabeled Use

Disclosure of Discussion of Non-FDA–Approved Uses for Pharmaceutical Products and/or Medical Devices
The University of Virginia School of Medicine, as an ACCME provider, requires that all faculty presenters identify and disclose any off-label uses for pharmaceutical and medical device products. The University of Virginia School of Medicine recommends that each physician fully review all the available data on new products or procedures prior to clinical use.

All faculty have indicated that they have not referenced unlabeled or unapproved uses of drugs or devices.


The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of the University of Virginia School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.